E4412; A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hodgkin Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
Inclusion Criteria
Must have pathologically confirmed relapsed or refractory classical Hodgkins Lymphoma
Must have relapsed after first line chemotherapy
Exclusion Criteria
Women must not be pregnant or breast-feeding
Evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 92% while breathing room air
Evidence of prior malignancy
Have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.